What GMP Certification Actually Means for Peptide Manufacturers

"GMP certified" is the most abused phrase in peptide supplier marketing.

Some vendors slap it on their site because a raw material supplier two tiers up holds ISO 9001. Others use it interchangeably with "produced in a clean room." A few actually mean they have passed an FDA or EMA inspection.

Here is how to tell the difference.

FDA cGMP vs. EU GMP vs. PIC/S GMP

Three frameworks, practically identical in standard. The differences are administrative.

FDA cGMP. Evaluates facilities against ICH Q7 across six areas: Quality, Facilities, Materials, Production, Lab Control, Packaging. The "c" means "current." Standards update continuously. Inspections follow Compliance Program 7356.002F for APIs.

EU GMP. EudraLex Volume 4. Requires a Qualified Person to certify each batch before release. The EMA's new synthetic peptide guideline (June 1, 2026) sets impurity thresholds at 0.1% reporting, 0.5% identification, 1.0% qualification.

PIC/S GMP. Nearly identical to EU GMP. Uses "authorised person" instead of "Qualified Person." Limited to manufacture only (not import/distribution). The FDA joined PIC/S in 2011.

Bottom line: A facility that passes an FDA inspection generally satisfies EU and PIC/S. The differences are in batch release authority and documentation format.

ISO 9001 Is Not GMP

This is the most common substitution in the research peptide market.

GMP is mandatory, enforced by health authorities with on-site inspections and legal action. ISO 9001 is a voluntary quality framework that applies to any industry, from auto parts to accounting to logistics. It does not mandate pharmaceutical manufacturing controls.

Bachem's knowledge center says it directly: ISO 9001 does not replace GMP. A sterile drug manufacturer cannot rely on ISO 14644-1 for cleanroom qualification; they need microbiological data to meet cGMP.

If a vendor advertises "GMP certified" and provides only an ISO 9001 certificate, that is a red flag. They may also be referencing an affiliate manufacturer's ISO status rather than their own compliance.

How to Verify a GMP Claim

EU / EEA: EudraGMDP database. Search by certificate number, DUNS, or site name. GMP certificates expire after three years unless extended.

United States: FDA Data Dashboard. The FDA does not issue GMP certificates. It publishes inspection results as NAI, VAI, or OAI. FDA eCPP certificates expire after 24 months.

Daily use: Ask for the EudraGMDP listing or FDA inspection history. A legitimate manufacturer provides this immediately. If they cannot or will not, the claim is unverifiable. Treat it as marketing, not documentation.

What Inspectors Actually Check

FDA Compliance Program 7356.002M focuses on these areas at peptide facilities:

Cross-contamination controls in multi-product facilities handling highly potent materials. Cleaning validation for chromatography columns is heavily scrutinized.

Equipment integrity. API-contact surfaces are inspected for scratches, stains, or grooves that could cause particulate contamination.

Impurity characterization. Facilities must characterize process-related impurities (residual solvents) and peptide-specific impurities (deletion sequences, truncation products, oxidation variants).

Stability data must include investigation of high molecular weight aggregate formation.

The EMA's 2026 guideline closes a loophole: all chemical transformation steps after the "API Starting Material" must be performed under GMP. No more "we only purified under GMP."

Common Violations (2025-2026)

On March 19, 2026, the FDA revised Import Alert 66-80 to allow detention of GLP-1 APIs without physical examination. They have assessed 48 GLP-1 API sites worldwide.

Recent warning letters cited:
Harbin Jixianglong: Poor HPLC resolution, data falsification (May 2026).
Hubei Gedian Humanwell: Scratched vessels, uncleaned equipment (June 2026).
Darmerica: Mislabeled GLP-1 APIs as "custom peptide" (December 2025).
Pink Pony Peptides: Sold unapproved "GLP-2 TZ" and "GLP-3 RT" (March 2026).
Sanofi: Used non-GMP instructions to bypass validated procedures (January 2025).

The pattern: the FDA does not care what your label says if your marketing makes therapeutic claims. Totality of marketing determines compliance.

Who Actually Has It

Bachem. Inspected by FDA, EMA, Swissmedic, PMDA, CDE, ANVISA. FDA license for Vista, CA facility (audited 2024). Reports zero supplier qualification queries.

CordenPharma. 11 cGMP facilities. Frankfurt certified January 2025 for expanded peptide capacity. Plankstadt passed ANVISA and MFDS with zero observations.

These are the benchmark. If a supplier claims GMP but cannot produce comparable credentials, the burden of proof is on them.

Why It Still Matters for Research Peptides

Even for RUO: the same failures that trigger FDA warning letters (inadequate testing, data falsification, contamination) affect product quality regardless of intended use. A manufacturer that cuts GMP corners is more likely to ship wrong identity or undetected impurities.

Our directory tags 82 suppliers as GMP certified. Verify each claim using the databases above. A GMP claim without documentation is just marketing copy.